PVSRIPO’s Unique Mechanism of Action Generates the Polyfunctional T Cells Required for Antitumor Immunity
- Preclinical studies provide evidence that PVSRIPO’s nonlethal infection of antigen presenting cells (APCs) stimulates a key innate immune pathway, resulting in a sustained, robust type-I/III interferon-dominant inflammatory response1
- Minimal release of unwanted cytokines associated with severe cytokine release syndrome
- Clinical responses were observed in both injected and noninjected lesions during the phase 1 trial in advanced PD-1/L1–refractory melanoma2
- This suggests a systemic antitumor immune response, which is being evaluated in the ongoing LUMINOS-102 phase 2 trial
- Because polio vaccination is nearly universal and leads to strong, lifelong immunity, administration of PVSRIPO triggers an immune memory response that may augment PVSRIPO’s activity
- Brown MC, et al. Nature Commun. 2021;12:1858.
- Beasley GM, et al. J Immunother Cancer. 2021;9:e002203. doi:10.1136/jitc-2020-002203